Cytori Therapeutics, Inc. Announces Resignation of John D. Harris as Vice President and General Manager of Cell Therapy
February 09, 2018 at 04:56 pm
Share
John D. Harris, Vice President and General Manager of Cell Therapy of Cytori Therapeutics, Inc. has tendered his notice of resignation from the Company, which resignation is effective as of May 1, 2018. Harris has indicated his intention to resign, though it is expected that he will be available to perform consulting services for the Company, as requested.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.